Design of amidobenzimidazole STING receptor agonists with systemic activity
By J. Ramanjulu, G. S. Pesiridis, Jingsong Yang, N. Concha, Robert R. Singhaus, Shuyun Zhang, Jean-Luc Tran, Patrick Moore, Stephanie Lehmann, H. Eberl and 35 more. Nature, 2018
746 citations recorded by the source corpus.
Subfields: Immunology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/e9a3cce6a7c52be54a65965dcefc89117742cd4a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022, background): “Recently, some novel STING agonists such as diABZI and MSA-2 have been developed which could be systemically administrated [268, 269].”
- DUSP11-mediated control of 5′-triphosphate RNA regulates RIG-I sensitivity (2020, background): “Agonists of STING and RIG-I have shown promise in mouse models as standalone or adjuvants for enhancing immunotherapies (Elion et al. 2018; Ramanjulu et al. 2018; Heidegger et al. 2019; Jiang et al. 2019).”